Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Nat Rev Rheumatol. 2018 May;14(5):269-278. doi: 10.1038/nrrheum.2018.41. Epub 2018 Apr 12.
The idiopathic inflammatory myopathies (IIMs; also known as myositis) are a heterogeneous group of disorders in which a common feature is chronic inflammation of skeletal muscle, leading to muscle weakness. Other organs are frequently affected in IIMs, such as the skin, joints, lungs, gastrointestinal tract and heart, contributing to morbidity and mortality. Currently, IIMs are most often subclassified into polymyositis, dermatomyositis and inclusion body myositis, but this subclassification has limitations as these subgroups often have overlapping clinical and histopathological features, and outcomes vary within the subgroups; additionally, subgroups without considerable myopathy are not included. A new way of subgrouping patients could be on the basis of the presence of myositis-specific autoantibodies. These autoantibodies are associated with distinct clinical features and, moreover, can help to identify subsets of IIMs in which extramuscular symptoms, such as skin manifestations, arthritis or interstitial lung disease, might be the presenting or predominant feature when muscle symptoms are mild or absent. The recognition that subphenotypes with single-organ involvement other than muscles exist is important for identifying patients with early disease, for clinical care demanding team management and in designing clinical studies to improve our understanding of this heterogeneous disease to develop new therapies.
特发性炎性肌病(IIM;也称为肌炎)是一组异质性疾病,其共同特征为骨骼肌慢性炎症,导致肌肉无力。IIM 常累及其他器官,如皮肤、关节、肺、胃肠道和心脏,导致发病率和死亡率升高。目前,IIM 最常分为多发性肌炎、皮肌炎和包涵体肌炎,但这种分类存在局限性,因为这些亚组通常具有重叠的临床和组织病理学特征,且亚组内的预后存在差异;此外,不伴有明显肌病的亚组也不包括在内。一种新的分组方法可以基于肌炎特异性自身抗体的存在。这些自身抗体与特定的临床特征相关,此外,还可以帮助确定 IIM 的亚组,其中肌肉症状轻微或不存在时,肌肉外症状(如皮肤表现、关节炎或间质性肺病)可能是首发或主要特征。认识到除肌肉以外的单一器官受累的亚表型的存在对于识别早期疾病患者、需要团队管理的临床护理以及设计临床研究以提高我们对这种异质性疾病的理解以开发新疗法都很重要。